Abstract
Patients with benign prostatic hyperplasia (BPH) often receive $\alpha$-blockers as first-line therapy for lower urinary tract symptoms (LUTS). However, many individuals continue to experience residual storage symptoms such as urgency and nocturia. While antimuscarinics, $\beta$3-agonists, and desmopressin are effective add-on options, evidence for the optimal first choice has been lacking. This systematic review and network meta-analysis (NMA) investigated the clinical benefits of these medications when added to $\alpha$-blockers. Analyzing 15 randomized controlled trials (RCTs), the study found that desmopressin and imidafenacin offer superior efficacy for total symptom improvement and specific storage issues, respectively.
Introduction: Addressing Residual Symptoms in BPH
Benign Prostatic Hyperplasia (BPH) is a common condition in aging men, characterized by lower urinary tract symptoms (LUTS). Standard treatment typically begins with $\alpha$-blockers to improve urine flow. Despite this, a significant portion of patients suffers from persistent "storage symptoms"—including urgency, frequent daytime urination, and nocturia—which are often more disruptive to quality of life than voiding issues.
Clinicians can choose from several drug classes to supplement $\alpha$-blocker therapy: antimuscarinics, $\beta$3-agonists, and antidiuretics. However, without head-to-head trials, determining the most effective "second-step" medication has been challenging. This study utilizes a network meta-analysis to rank these therapies and provide a clearer clinical roadmap.
Methods and Data Synthesis
The researchers conducted a Systematic Review and Network Meta-Analysis (NMA) of 15 RCTs involving 4,875 patients. Unlike traditional meta-analyses, an NMA allows for the comparison of multiple treatments by using a common comparator—in this case, $\alpha$-blocker monotherapy—as a bridge.
The primary tool for ranking was the Surface Under Cumulative Ranking curves (SUCRA). A higher SUCRA percentage indicates a higher probability that a treatment is the most effective for a given outcome. The study evaluated five key clinical metrics: International Prostate Symptom Score (IPSS) Total Score, IPSS Storage Sub-score, Nocturia (nighttime voids), Micturition (daytime frequency), and Urgency.
Key Findings and Treatment Rankings
The analysis revealed distinct advantages for specific medications depending on the patient's primary complaint:
- Desmopressin for Nocturia and Total Symptoms: Desmopressin emerged as the top-ranked treatment for both the total IPSS score and the reduction of nighttime voids (SUCRA: 100% for both). This highlights its potent role in managing fluid-related storage issues.
- Imidafenacin for Storage and Frequency: Among antimuscarinics, imidafenacin showed the highest efficacy for the IPSS storage sub-score (SUCRA: 93.2%) and daytime micturition frequency (SUCRA: 98.3%). Its specific affinity for M3 and M1 receptors likely contributes to this performance.
- Mirabegron as a Consistent Performer: Mirabegron ($\beta$3-agonist) and imidafenacin were the only two medications to show statistically significant improvements across all five assessed outcomes. Mirabegron is particularly noted for its favorable safety profile, often causing fewer side effects like dry mouth compared to antimuscarinics.
- Tolterodine for Urgency: For patients where sudden urgency is the primary concern, tolterodine was ranked highest (SUCRA: 92.2%).
Discussion and Limitations
While the study provides a robust hierarchy of effectiveness, several factors must be considered in clinical practice. The trials analyzed were relatively short-term (6–12 weeks), meaning the long-term persistence of these benefits and potential late-onset side effects require further study.
Additionally, while the NMA focused on efficacy, safety profiles vary significantly between classes. For instance, desmopressin carries a risk of hyponatremia, while antimuscarinics are frequently associated with dry mouth and constipation. The choice of the initial $\alpha$-blocker (e.g., tamsulosin vs. silodosin) also varied across trials, which may introduce minor heterogeneity in the results.
Conclusion
For BPH patients with persistent storage symptoms despite $\alpha$-blocker treatment, adding a second medication is highly recommended. Based on SUCRA rankings, desmopressin and imidafenacin should be considered high-priority options due to their superior efficacy in reducing symptom severity and frequency. Mirabegron remains a strong, well-rounded alternative with a potentially better tolerability profile.
Summary updated